Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection

Samrajya Lakshmi Yeruva, Prashant Kumar, Seetharam Deepa, Anand K. Kondapi

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Aim: We report here the development of tenofovir- and curcumin-loaded lactoferrin nanoparticles (TCNPs) as an HIV-microbicide. Materials & methods: TCNPs were subjected to various physicochemical characterization experiments, followed by in vitro and in vivo experiments to assess their efficacy. Results: TCNPs had a diameter of 74.31 ± 2.56 nm with a gross encapsulation of more than 61% for each drug. Nanoparticles were effective against HIV-1 replication, with an IC50 of 1.75 μM for curcumin and 2.8 μM for tenofovir. TCNPs provided drug release at the application site for up to 8-12 h, with minimal leakage into the systemic circulation. TCNPs showed spermicidal activity at ≥200 μM and induced minimal cytotoxicity and inflammation in the vaginal epithelium as revealed by histopathological and ELISA studies. Conclusion: We demonstrated that TCNPs could serve as a novel anti-HIV microbicidal agent in rats. </inline-graphic.

Original languageEnglish (US)
Pages (from-to)569-586
Number of pages18
JournalNanomedicine
Volume16
Issue number7
DOIs
StatePublished - Mar 2021

Keywords

  • curcumin
  • HIV
  • lactoferrin
  • microbicide
  • nanoparticles
  • TCNPs
  • tenofovir

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'Lactoferrin nanoparticles coencapsulated with curcumin and tenofovir improve vaginal defense against HIV-1 infection'. Together they form a unique fingerprint.

Cite this